EZH2 and follicular lymphoma: Although this seems conflicting with EZH2 ability to enhance proliferation, the proliferative capacity of a tumor does not necessarily correlates with aggressiveness or stage of the disease, as recently exemplified with the pediatric-type follicular lymphoma, an indolent type of follicular lymphoma with high proliferation index.34, 35 Moreover, proliferative tumors respond better to chemotherapy as a higher number of cells are in cycling and can be targeted, as all patients included in the PRIMA trial received rituximab chemotherapy as induction regimen.